California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a ...
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in ...
Swedish neuroscience specialist BioArctic (Nasdaq Stockholm: BIOA B) said partner Eisai expects Alzheimer’s disease therapy ...
Vetter is celebrating the start of construction on its new site in Saarlouis with a traditional ground-breaking ceremony today.
US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne ...
The European Commission (EC) has granted marketing authorization to expand the approved indication for Pfizer’s Hympavzi ...
Japan’s largest drugmaker Takeda today announced financial results for the fiscal year 2025 (period ended March 31, 2026).
The global DNA synthesis market is projected to grow from $5.7 billion in 2025 to $30.4 billion by 2035, according to a new ...
Italian drugmaker Recordati reported first-quarter 2026 revenue of 713 million euros ($775 million) on Tuesday, up 5% year-on ...
Spanish drugmaker Almirall has reported first-quarter 2026 results in line with expectations, driven by continued strong ...
US biotech Rigel Pharmaceuticals is betting heavily on the newly-approved breast cancer therapy Veppanu (vepdegestrant), ...
Danish CNS specialist Lundbeck reported that total revenue for the first quarter of 2026 grew by +21% constant exchange rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results